Takeaway

• Compared with glucose-lowering drugs for type 2 diabetes (T2D) with lower hypoglycaemic potential, sulphonylureas had higher odds for all-cause mortality (ACM), major adverse cardiovascular events (MACE), myocardial infarction (MI), and hypoglycaemia.
• Among individual sulphonylureas, glimepiride may be the safest.

Why this matters

• Sulphonylureas are low in cost and effectively...